EACS Conference 11-14 November 2009 Cologne

Plenary Session

Earlier Recognition of HIV: A Pressing Need
Prof. Jens Lundgren, MD DMSc. Co-chair "HIV IN EUROPE Initiative" steering committee. University of Copenhagen & State University Hospital, Denmark
presentation

Oral

1 Estimating AIDS and non-AIDS related deaths for patients with missing death data in the EuroSIDA cohortJustyna D. Kowalska, Amanda Mocroft, Bruno Ledergerber, Robert Colebunders, Mattie Ristola, Josip Begovac, Helen Sambatakou, Court Pedersen, Jens D. Lundgren, Ole Kirk
oral

2 Improvements in mortality between 2002-2007 across Europe : Differences between regions of Europe A Mocroft, B Gazzard, A Karlsson, I Karpov, S D Wit, J v Lunzen, C Katlama, K Zilmer, O Kirk, JD Lundgren on behalf of the EuroSIDA study group.
oral

3 Tuberculosis (TB) among HIV-1 infected patients across Europe: change over time and risk factors Alexej Kruk, Wendy Bannister, Daria Podlekareva, Nelly Chensova, Aza Rakhmanova, Andrzej Horban, Pere Domingo, Jens D Lundgren, Amanda Mocroft, Ole Kirk, for the EuroSIDA Study Group.
oral

4 Survival and prognostic factors for patients with non-AIDS defining malignancies (NADM) Csaba Kosa, Joanne Reekie, Johannes Bogner, Pierre-Marie Girard, Gerd Fätkenheuer, Antonio Chiesi, Martin Fisher, Frederik Neess-Engsig, Amanda Mocroft, Ole Kirk

5 Has the uptake of treatment for chronic hepatitis C virus infection (CHC) in HIV-positive patients in Europe changed over time? A. Mocroft, M. Vogel, M. Beniowski, C. Pradier, M. Battegay, D. Jevtovic, V. Soriano, L. Peters, J. Lundgren,J.K. Rockstroh, for the EuroSIDA Study Group.
oral

6 Health Care Index (HCI) and Outcome following a diagnosis of tuberculosis (TB) O Kirk, A Mocroft, DN Podlekareva, FA Post, V Riekstina, JM Miro, H Furrer, M Bruyand, AM Panteleev, AG Rakhmanova, E Girardi, MH Losso, JJ Toibaro, J Caylá, RF Miller, N Obel, A Skrahina, N Chentsova, JD Lundgren, for the HIV/TB study group.
oral

7 Epidemiological and virological characteristics of chronic HBV infection in HIV-positive patients in Europe from 1994 - 2006. Martin Vogel, Amanda Mocroft, Lars Peters, Francisco Antunes, Nikolai Kirkby, Stephane De Wit, Antonella d’Arminio Monforte, Robert Flisiak, Jürgen K. Rockstroh, Vincent Soriano for the EuroSIDA Study Group.
oral

8 CD4 count, viral suppression, prophylaxis and the risk of primary pneumocystis pneumonia in the cart era - the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Amanda Mocroft, Jose M. Miro, Hansjakob Furrer, for the Opportunistic Infections Working Group.
oral

9 Mortality rates of elderly HIV-infected adults treated with antiretroviral are closer to general population than in younger patients. Charlotte Lewden on behalf of COHERE.

Posters

1 Dialysis and renal transplantation in HIV-infected patients: a European survey in 2008 A Mocroft, JC Trullas, F Cofan, J Tourret, A Moreno, C Isnard, C Fux, C Katlama, P Reiss, J Lundgren, JM Gatell, O Kirk, JM Miro and the EuroSIDA Investigators.
poster

2 Predictors of having a resistance test following confirmed viral load (VL) failure of cART. ZV Fox, AN Phillips, A Cozzi-Lepri, A d'Arminio Monforte, A Karlsson, A Mocroft, G Kronborg, J Kjaer, B Clotet and JD Lundgren for the EuroSIDA study group.
poster

3 Prevalence of HIV-1 drug resistance over calendar time in EuroSIDA patients receiving antiretroviral therapyWendy Bannister, Alessandro Cozzi-Lepri, Jesper Kjær, Bonaventura Clotet, Adriano Lazzarin, Jean-Paul Viard, Gitte Kronborg, Dan Duiculescu, Marek Beniowski, Ladislav Machala and Andrew Phillips.
poster

4 Presence of drug resistance during the course of treatment in patients who developed virological failure to the three original classes of antiretroviral drug. Frank de Wolf on behalf of COHERE.

5 Viral load outcome after virologic failure of the three original antiretroviral drug classes in 2000-2007. Dominique Costagliola on behalf of COHERE.

6 HIV-related Hodgkin lymphoma in the era of HAART: incidence and survival in a European mulit-cohort study. Julia Bohlius on behalf of COHERE.

47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, October 2009

Oral

1 Can sequential procalcitonin or neopterin measurements help improve survival in the ICU? J Jensen, B Lundgren, J D Lundgren.

2 Efficacy and safety of Procalcitonin (PCT) guided antimicrobial chemotherapy (AMC) in the intensive care unit (ICU): Final results from a ransomised controlled trial of 1,200 patients. J Jensen, L Hein, M Bestle, K Thornberg, J Løken, M Steensen, Z Fox, H Tousi, P Søe-Jensen, J Kjær, A Ø Lauritsen, D Strange, P L Petersen, N Reiter, S Hestad, K Thormar, M H Andersen, T Mohr, P Fjeldborg, K M Larsen, N Drenck, C Østergaard, B Lundgren, J Grarup, J Lundgren.

Poster

1 Post-transplant CMV infection (CMVI): Therapeutic and immunological risk factors. C da Cunha-Bang, S Sørensen, M Iversen, H Sengeløv, J Hillingsø, S Mortensen, Z Fox, J Lundgren, The Herpes Virus Transplantation Study Group at the State University Hospital (Rigshospitalet), State University Hospital & Univeristy of Copenhagen, Denmark.
Poster 244 KB.

Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts, Montpellier, September 2009

Poster

1 A Bioinformatic Approach to Indentify New Potential Resistance Relevant Amino Acid Substitution (AAS) in HIV-1 Protease. CM Frederiksen, J Kjær, A Cozzi-Lepri, Z Fox and JD Lundgren.
Poster (428 KB)

5th European Conference on Clinical and Social Research on AIDS and Drugs, Vilnius, April 2009

Poster

1 A regional comparison of the mode of HIV-1 transmission in patients enrolled in the EuroSIDA study. J Tverland, J Reekie, M Paulsen, A Mocroft, A Vassilenko, V Uzdaviniene, N Zakharova, N Chentcova, M Ellefson, O Kirk for EuroSIDA. Poster 72 KB

7th European Drug Resistance Workshop, Stockholm, March 2009

Poster

1 Predictors of having a resistance test following at least one episode of viral load (VL) failure of cART: data from EuroSIDA. ZV Fox, AN Phillips, A Cozzi-Lepri, A d'Arminio Monforte, A Karlsson, A Mocroft, G Kronborg, J Kjaer, B Clotet and JD Lundgren for EuroSIDA.
Poster 191 KB

16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009

Oral Presentations

1Risk of myocardial infarction (MI) in those exposed to specific antiretroviral drugs (ARVs) from the protease (PI), non-nucleoside reverse transcriptase (NNRTI) and nucleos(t)ide reverse transcriptase inhibitor (NRTI) drug classes: the D:A:D Study. JD Lundgren, P Reiss, S W Worm, W El-Sadr, S DeWit, R Weber, A d'Arminio Monforte, O Kirk, E Fontas, F Dabis, M G Law, N Friis-Møller, A N Phillips, C Sabin, on behalf of the D:A:D study group.
Oral 115 KB

2 High hepatitis C viremia is associated with an increased risk for mortality in HIV/Hepatitis C virus coinfected individuals. J Rockstroh, L Peters, V Soriano, P Reiss, A d'Arminio Monforte, M Beniowski, M Losso, O Kirk, B Kupfer, A Mocroft on behalf of the EuroSIDA Study Group. Oral 111 KB

3 Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: Results from the D:A:D study. C Smith, R Weber, S Worm, A Phillips, R Thiebaut, N Friis-Møller, C Pradier, O Kirk, A d'Arminio Monforte, W El Sadr, P Reiss, J Lundgren, C Sabin on behalf of the D:A:D Study Group. Oral 113 KB

4 Effect of Interleukin-2 on Clinical Outcomes in Patients with a CD4⁺ Cell Count of 300/mm³: Primary Results of the ESPRIT Study. Marcelo Losso. Oral

5.Effect of Interleukin-2 on Clinical Outcomes in Patients with CD4⁺ Cell Count 50 to 299/mm³: Primary Results of the SILCAAT Study.
Yves Levy and SILCAAT Sci Committee. Oral

Posters

1.Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients. L Peters, A Mocroft, V Soriano, J Rockstroh, B Ledergerber, A Karlsson, B Knysz, C Pradier, K Zimler, JD Lundgren for the EuroSIDA study group. 
Poster 139 KB

2.Mutation A376S in the RT connection domain is associated with an increased risk of virological failure to nevirapine-  based therapy in NNRTI-naïve HIV-infected subjects in the EuroSIDA Study. R Parades, W Bannister, A Cozzi-Lepri, C Pou, R Bellido, J Bogner, P Gargalianos, D Bánhegyi, B Clotet, JD Lundgren and the EuroSIDA study group. 
Poster 247 KB

3.Serious Fatal and Non Fatal Non-AIDS Defining Illnesses (non-ADI) in Europe. A. Mocroft, P Reiss, J Gasiorowski, B Ledergerber, A Chiesi, J Gatell, A Rakhmanova, MA Johnson, O Kirk, JD Lundgren for the EuroSIDA study group. 
Poster 93 KB

4.Relationship between Current Level of Immunodeficiency and Non-AIDS malignancies. J Reekie, A Mocroft, F Engsis, A d'Arminio Monforte, A Wiercinska-Drapalo, P Domingo, F Antunes, N Clumeck, O Kirk, JD Lundgren for the EuroSIDA study group. 
Poster 111 KB

5.Interruption of Antiretroviral Therapy and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in SMART Viral Hepatitis Coinfected Participants and Matched Controls. L Peters, J Neuhaus, A Mocroft, V Soriano, J Rockstroh, G Dore, M Puoti, E Tedaldi, B Clotet, B Kupfer, JD Lundgren, MB Klein for the INSIGHT SMART Study Group. 
Poster 337 KB

6.Risk of extensive triple class virologic failure of the three original antiretroviral drug classes among people followed from therapy initiation with NNRTI or ritonavir-boosted PI regimens. R Lodwick on behalf of the PLATO II project team of COHERE. 
Poster 159 KB

7.Impact of cART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin-Lymphoma - European Multi-Cohort Study. J Bohlius, M Egger, on behalf of the COHERE study group. 
Poster 517 KB

8. Antiretroviral Therapy (ART) Reinitiation and Hepatitis B Virus (HBV) Rebound among HIV – HBV Coinfected Patients following ART interruption in the SMART Study. V. Soriano. Poster

9.Does Treatment Interruption within the SMART trial lead to changes in hepatitis C virus load in HIV-/HCV-coinfected patients? J Rockstroh. Poster

10.Does Activation of Inflammatory and Coagulation Pathways Independently Predict the Development of Opportunistic Disease in Patients with HIV Infection? A Rodger. Poster